Asmerom T Sengal
Dr Asmerom Sengal is a clinician scientist passionate about improving patient outcomes through innovative research. He graduated with a Doctor of Medicine (MD) in 2009 and completed my specialisation in Anatomic Pathology. Dr Sengal completed his PhD training in Molecular Oncology under the supervision of Prof Pollock at QUT in 2020. His research is focused on biomarker discovery, preclinical model development and drug screening. He developed and validated novel BaseScope RNA ISH Techniques in collaboration with ACD Bio. Using this assay, he discovered that FGFR2c is an independent prognostic and predictive biomarker in endometrial cancer. He established and characterised several EC PDXs and Patient-derived organoids (PDOs) that are vital for drug testing. Using the established PDXs and PDOs, He revealed that FGFR2c is a novel target in EC. He also demonstrated the dependency of the EC organoid growth on FGFR2c/FGF2 signalling using FGFR2 shRNA-mediated knockdown.
He published over 20 articles and conference papers in prestigious peer-reviewed international journals including Clin Can Res, Genome Medicine and Nat Precision Oncology. Dr Sengal received several seeding funds including Cure Cancer that supported the establishment of novel PDOs from metastatic and recurrent endometrial cancers that have unmet clinical needs. Dr Sengal is an active member of several professional societies, including ANZGOG and an active academic editor in PLOS One Journal.
Dr Sengal also received several awards including QUTPGRA 2016, Cure Cancer Australia Research of the Year 2024 (Finalist), Publication of the Year 2024 ECR/MCR Category CGPH QUT.
Abstracts this author is presenting: